Clearmind Medicine (NASDAQ:CMND; FSE:CWY0) has announced that its proprietary MEAI-based binge behavior regulator program has received patent approval from the Macau International Intellectual Property Office, a special...
Clearmind Medicine (NASDAQ:CMND; FSE:CWY0) is discovering and developing safe, novel psychedelic-derived therapeutic candidates with its new psychoactive molecule, 5-Methoxy-2-aminoindane (MEAI), to address widespread...